US FDA Commissioner Nominee Not ‘Pro-Industry Choice,’ GLP-1 Compounding Could Be First Clash

Martin Makary’s ties to a compounder and telehealth company offering compounded GLP-1s may concern the drug industry and raise questions about his fundamental beliefs in the FDA’s role regulating drug manufacturing.